NICE backs UCB drug as first uncontrolled gMG therapy
UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.
Newsletters and Deep Dive digital magazine
UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.
The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main driving factor.
OxyContin manufacturer Purdue is on the brink of a bankruptcy deal that could put years of opioid liability litigation in its rearview mirror.
There has been a major data security lapse at the UK Biobank, with "de-identified" data from its 500,000 volunteers listed for sale in China.
Editor's Picks
Newsletters and Deep Dive
digital magazine